MS
Insider
Mayur Ian Somaiya
Chief Financial OfficerMayur Ian Somaiya (Chief Financial Officer) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in NewAmsterdam Pharma Company N.V. (NAMS). The largest single filing was $3.2M of NAMS (99,100 sh across 4 lots, as filed), executed Jan 20.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$3.4M
shares × price, as filed
Last traded
Jan 21
Filed Jan 22
Median ADV $32.2M across their filed names
Open performance→Volume by month
Buys $0
Sells $4.7M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
NAMSRecent filings
NAMSSALE
NewAmsterdam Pharma Company N.V.
View filing →
$3.2M99,100 sh across 4 lots
Exec Jan 20
Filed Jan 22 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. View filing → $170K
5,118 sh × $33.25
Exec Jan 5
Filed Jan 7 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. View filing → $1.3M
58,478 sh across 3 lots
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET